Parkman Healthcare Partners LLC Takes $20 Million Position in Insulet Corporation $PODD

Posted by Brian Himes on Aug 25th, 2026

Parkman Healthcare Partners LLC acquired a new stake in shares of Insulet Corporation (NASDAQ:PODD – Free Report) during the second quarter, Holdings Channel reports. The firm acquired 131,378 shares of the medical instruments supplier’s stock, valued at approximately $20,002,000. Insulet comprises 2.0% of Parkman Healthcare Partners LLC’s investment portfolio, making the stock its 17th largest holding.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Legal & General Group Plc bought a new position in Insulet during the 2nd quarter valued at $47,419,000. The Manufacturers Life Insurance Company acquired a new position in shares of Insulet during the 2nd quarter valued at $6,085,000. Whalen Wealth Management Inc. bought a new stake in shares of Insulet in the 2nd quarter worth $541,000. Algert Global LLC lifted its holdings in shares of Insulet by 75.7% in the second quarter. Algert Global LLC now owns 144,584 shares of the medical instruments supplier’s stock valued at $22,013,000 after buying an additional 62,277 shares during the period. Finally, OMERS ADMINISTRATION Corp acquired a new stake in shares of Insulet in the second quarter valued at $2,422,000.

Insulet News Roundup

Here are the key news stories impacting Insulet this week:

Positive Sentiment: CEO Ashley McEvoy purchased 1,100 Insulet shares at an average price of $147.47, an investment of approximately $162,200. The transaction increased her direct holdings by about 5% and may signal management confidence after the stock’s substantial decline. Insulet CEO share purchase article
Neutral Sentiment: Multiple law firms—including Rosen, Bragar Eagel & Squire, Levi & Korsinsky, and others—are soliciting investors who purchased PODD securities during periods generally spanning February 21, 2025, through May 26, 2026. Investors have until August 31, 2026, to seek appointment as lead plaintiff. These announcements largely repeat existing litigation information rather than represent new operating developments. Rosen Law Firm Insulet deadline article
Negative Sentiment: The lawsuit-related releases allege that Insulet and certain officers violated federal securities laws by failing to disclose issues associated with two voluntary Medical Device Corrections involving Omnipod insulin-delivery systems. The allegations reportedly concern systemic manufacturing defects and potential investor losses; they have not been proven in court. Continued legal publicity increases regulatory, financial, and reputational uncertainty for Insulet and is likely the main reason investor sentiment remains weak. Levi and Korsinsky Insulet class action article

Insider Activity at Insulet

In other news, Director Timothy C. Stonesifer bought 2,790 shares of the firm’s stock in a transaction on Wednesday, June 3rd. The stock was bought at an average cost of $143.51 per share, for a total transaction of $400,392.90. Following the completion of the acquisition, the director directly owned 9,041 shares in the company, valued at $1,297,473.91. This represents a 44.63% increase in their position. The purchase was disclosed in a filing with the SEC, which is available at this hyperlink. 0.36% of the stock is currently owned by insiders.

Insulet Trading Down 1.8%

Shares of NASDAQ PODD opened at $145.42 on Tuesday. Insulet Corporation has a 12 month low of $126.40 and a 12 month high of $354.88. The company has a market cap of $10.08 billion, a price-to-earnings ratio of 27.18, a P/E/G ratio of 1.17 and a beta of 1.10. The company has a quick ratio of 1.83, a current ratio of 2.48 and a debt-to-equity ratio of 0.65. The business has a fifty day simple moving average of $154.61 and a 200-day simple moving average of $183.56.

Insulet (NASDAQ:PODD – Get Free Report) last issued its quarterly earnings results on Wednesday, August 5th. The medical instruments supplier reported $1.66 earnings per share for the quarter, topping analysts’ consensus estimates of $1.47 by $0.19. The firm had revenue of $801.70 million for the quarter, compared to analysts’ expectations of $787.39 million. Insulet had a return on equity of 29.29% and a net margin of 12.29%.Insulet’s revenue was up 23.5% on a year-over-year basis. During the same quarter last year, the business posted $1.17 EPS. Insulet has set its FY 2026 guidance at 6.460- EPS. Sell-side analysts predict that Insulet Corporation will post 6.51 EPS for the current year.

Analyst Ratings Changes

A number of research analysts recently issued reports on the company. Bank of America lowered their target price on Insulet from $288.00 to $208.00 and set a “buy” rating on the stock in a report on Monday, May 18th. Weiss Ratings downgraded shares of Insulet from a “hold (c-)” rating to a “sell (d+)” rating in a report on Wednesday, June 24th. Wells Fargo & Company lowered shares of Insulet from an “overweight” rating to an “equal weight” rating and reduced their price objective for the company from $255.00 to $144.00 in a research report on Wednesday, August 5th. Deutsche Bank Aktiengesellschaft started coverage on shares of Insulet in a report on Tuesday, June 23rd. They issued a “buy” rating and a $190.00 target price on the stock. Finally, UBS Group cut their target price on shares of Insulet from $174.00 to $150.00 and set a “neutral” rating for the company in a research note on Thursday, August 6th. Fourteen analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $195.40.

View Our Latest Stock Analysis on PODD

Insulet Company Profile

(Free Report)

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.